Saturday 17 October 2026 Export COSM’s income statement to Excel — free account

Cosmos Health Inc.

Cosmos Health Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65.3 million, up 19.9% from fiscal 2024. In the quarter to June 2026, revenue grew 28.8%, EPS was flat, free cash flow grew 9.39% and total debt rose 15.3%, each against the same quarter a year earlier. Revenue growth for three consecutive years; insiders bought in the last twelve months.

0.33 0.01 −2.94%

Follow COSM

Alert me

Market cap: $33.9M
P/E: 0.0×
Fwd P/E: 25.1×
Dividend yield: —
F-score: 5/9
Altman Z: −2.50
Beneish M: −3.25
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 1.74

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	5	2	7	2	—	—	—	3	2	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 53.44%

Capital & Financial Ratios $m

Market Cap 33.85

Revenue 73.73

Net Income (24.39)

Free Cash Flow (12.45)

Net Debt 9.30

Current Ratio 1.05

Debt/Equity 0.57

P/E ratio 0.00

Fwd P/E 25.10

P/S ratio 0.27

P/B ratio 0.96

Past 5Y EPS Growth —

This Y EPS Growth 65.08%

Next Y EPS Growth 131.82%

Next Y revenue growth 23.79%

Next 5Y EPS Growth 62.88%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 80.70%

10-year low 10-year high

P/B against its own 10 years 88.59%

10-year low 10-year high

EV/Sales against its own 10 years 74.02%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	4	0	4	2
Receivables	21	15	22	21
Inventory	5	4	6	5
Other	—	—	—	—
	37	25	38	37

	2023	2024	2025	Q'26
Payables	12	12	17	14
ST’ Debt	7	7	9	9
Other	3	3	7	7
	24	26	38	35

Compound Annual Growth %

	10y	5y	3y
Sales	—	3.33%	9.04%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	0.00%	(22.31%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	18	19	—	—	—
’25	14	15	17	20	65
’24	15	13	12	14	54
’23	12	12	13	16	53
’22	13	13	12	12	50
’21	12	15	14	16	56
’20	12	13	14	16	55

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(1)	(2)	—	—	—
’25	0	(1)	(2)	(5)	(8)
’24	(3)	(1)	1	(4)	(8)
’23	(6)	(6)	(5)	1	(16)
’22	(2)	(1)	(2)	(10)	(15)
’21	(1)	(2)	(3)	(2)	(7)
’20	(1)	(5)	(4)	(1)	(12)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(2)	(1)	—	—	—
’25	0	(1)	(3)	(6)	(11)
’24	(3)	(1)	1	(5)	(9)
’23	(6)	(9)	(7)	(3)	(25)
’22	(2)	(1)	(2)	(10)	(15)
’21	(1)	(2)	(4)	(2)	(8)
’20	(1)	(5)	(4)	(1)	(12)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.06)	(0.10)	—	—	—
’25	(0.03)	(0.10)	(0.17)	(0.31)	(0.63)
’24	(0.11)	(0.15)	(0.45)	(0.45)	(1.17)
’23	(0.04)	(0.09)	(0.27)	(1.73)	(2.15)
’22	(7.75)	(23.25)	(2.00)	(3.96)	(33.16)
’21	(3.61)	(3.69)	(2.83)	(1.99)	(12.12)
’20	(0.91)	2.60	1.43	(1.57)	1.54

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	3.20	4.01	2.11	2.03	1.15	2.13	0.07	0.97	0.47	0.28	Analyst estimates 2026–2028 Powerpack
	High	8.20	10.65	12.50	4.00	5.65	7.77	23.84	7.44	1.58	1.32
People
People	Employees	—	1	1	68	85	95	102	123	149	163
	Revenue/emp, $m	0.00	30.01	37.08	0.58	0.65	0.59	0.49	0.43	0.37	0.40
Income, $m
Income, $m	Revenue	7	30	37	40	55	56	50	53	54	65
	Gross margin, %	8.90	6.52	6.50	9.23	14.55	14.81	11.83	8.15	7.92	12.10
	EBT	(1)	(6)	(9)	(3)	1	(8)	(13)	(19)	(16)	(19)
	EBT margin, %	(8.88)	(20.68)	(24.39)	(7.85)	2.16	(13.95)	(25.93)	(34.74)	(29.73)	(29.33)
	Net income	(1)	(6)	(9)	(3)	1	(8)	(14)	(19)	(16)	(19)
	Depreciation	0	1	6	1	0	1	2	1	1	1
Per share, $
Per share, $	Revenue	13.44	58.71	69.67	74.73	104.38	85.61	26.11	4.46	2.84	2.16
	Earnings	(1.20)	(12.15)	(17.02)	(6.21)	1.55	(11.42)	(33.16)	(2.15)	(1.17)	(0.63)
	Cash flow	(4.23)	(17.14)	(2.92)	(9.02)	(21.67)	(10.80)	(7.71)	(1.31)	(0.40)	(0.28)
	Capex	(0.03)	(0.11)	(0.95)	(1.27)	(0.22)	(1.36)	(0.19)	(0.77)	(0.07)	(0.07)
	Free cash flow	(4.26)	(17.24)	(3.87)	(10.29)	(21.89)	(12.16)	(7.90)	(2.07)	(0.47)	(0.35)
	Book value	(3.49)	(5.92)	(6.23)	(12.17)	(7.84)	6.67	20.37	3.01	1.28	0.61
	Shares, m	1	1	1	1	1	1	2	12	19	30
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	3.30	0.00	0.00	0.00	0.00	0.00
	P/S	0.61	0.18	0.06	0.03	0.05	0.04	0.21	0.31	0.24	0.23
	P/B	0.00	0.00	0.00	0.00	0.00	0.51	0.27	0.45	0.52	0.82
	EV/Sales	0.53	0.16	0.09	0.16	0.38	0.42	0.00	0.42	0.39	0.41
	EV/FCF	(1.67)	(0.54)	(1.65)	(1.15)	(1.81)	(3.04)	(0.01)	(0.90)	(2.34)	(2.52)
Cash, $m
Cash, $m	Operating cash flow	(2)	(9)	(2)	(5)	(12)	(7)	(15)	(16)	(8)	(8)
	Capex	0	0	(1)	(1)	0	(1)	0	(9)	(1)	(2)
	Free cash flow	(2)	(9)	(2)	(5)	(12)	(8)	(15)	(25)	(9)	(11)
Balance, $m
Balance, $m	Working capital	(2)	(4)	(4)	(7)	6	10	35	12	0	0
	Total debt	0	0	5	5	19	21	10	10	9	15
	Net debt	(1)	(1)	1	5	18	21	(11)	6	8	12
	Shareholders’ equity	(2)	(3)	(3)	(6)	(4)	4	39	36	25	18
Returns, %
Returns, %	ROA	(8.71)	(90.03)	(57.77)	(14.80)	2.42	(33.44)	(108.87)	(38.47)	(37.20)	(31.96)
	ROIC	0.00	0.00	0.00	0.00	11.94	(11.11)	(16.26)	(32.58)	(29.66)	(34.86)
	ROE	25.14	259.79	285.59	67.48	(15.46)	(14,274.32)	(292.90)	(68.46)	(73.88)	(89.13)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
CAH Cardinal Health, Inc.	$58.8B	35.0×	23.3×	+5.84% (above 0%: growing)	+68.32% (above 0%: growing)	+10.87% (above 0%: growing)	4.02%	1.14%	Compare
HSIC Henry Schein, Inc.	$9.7B	25.0×	18.5×	+6.73% (above 0%: growing)	+16.90% (above 0%: growing)	+140.91% (above 0%: growing)	31.84%	4.95%	Compare
AHG Akso Health Group Sponsored ADR	$1.2B	— (loss-making)	— (loss-making)	+263.89% (above 0%: growing)	n/m	−12,975.04% (below 0%: shrinking)	0.00%	0.00%	Compare
FOCL FocalTherics	$154.8M	— (loss-making)	— (loss-making)	+38.85% (above 0%: growing)	n/m	+21.49% (above 0%: growing)	55.59%	(60.83%)	Compare
COSM Cosmos Health Inc.	$33.9M	— (loss-making)	25.1×	+28.76% (above 0%: growing)	n/m	+9.39% (above 0%: growing)	7.96%	(15.41%)
ACH Accendra Health, Inc.	$20.1M	— (loss-making)	— (loss-making)	−10.07% (below 0%: shrinking)	n/m	−1,624.82% (below 0%: shrinking)	42.95%	(5.73%)	Compare
HKPD Cellyan Biotechnology Co., Ltd	$17.1M	—	—	—	—	−90.45% (below 0%: shrinking)	—	—	Compare
YI 111, Inc. Sponsored ADR	$16.0M	— (loss-making)	— (loss-making)	−29.61% (below 0%: shrinking)	n/m	−185.70% (below 0%: shrinking)	5.33%	(0.85%)	Compare
SNYRQ Synergy CHC Corp.	$1.3M	— (loss-making)	1.6×	−32.77% (below 0%: shrinking)	n/m	−148.51% (below 0%: shrinking)	72.29%	(10.32%)	Compare
Median of peers	$87.5M	—	18.5×	+5.84%	—	−119.48%	31.84%	(0.85%)

All 11 Medical Distribution stocks →

Cosmos Health Inc. (COSM) key facts

Strength: Cosmos Health Inc.’s revenue for fiscal 2025 (year ended December 2025) was $65.3 million, up 19.9% from fiscal 2024.
Cosmos Health Inc. (COSM) is a Medical Distribution company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, COSM traded at $0.33, a market capitalization of $33.9 million.
Return on equity was −89.1% and debt-to-equity 0.57.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is −2.50 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.